Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy) | Infectious Agents and Cancer | Full Text
Anti-Spike protein assays to determine post-vaccination antibody levels: a head-to-head comparison of five quantitative assays | medRxiv
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination - Wilkins - 2022 - Clinical & Translational Immunology - Wiley Online Library
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination | npj Vaccines
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
Protection in Healthcare and Non-Healthcare Work Settings Mask Use
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article - ScienceDirect
Frontiers | IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine
WHO standards for COVID-19 established by the ECBS in Dec 2020
Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | Nature Medicine
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
Clinical Chemistry and Laboratory Medicine (CCLM)
Vaccines | Free Full-Text | Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays | Microbiology Spectrum
Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT) | Scientific Reports
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | Nature Medicine
Anti-Spike protein assays to determine post-vaccination antibody levels: a head-to-head comparison of five quantitative assays | medRxiv
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents | Scientific Reports
